For example sorafenib, an FDA-approved drug for thyroid, liver and kidney cancers, potently binds to FLT3 and FLT3-ITD with Kd values of 13 nM and 95 nM respectively and has shown activity against AML in the clinic [32]. Here, FLT3 is linked to kidney cancer.